Leukemia and Lymphoma Research

Providing High Quality and Internationally Recognized Drug Development and Clinical Research for Blood Cancer

The Sarah Cannon Blood Cancer Research Consortium is a network of premier hematology research investigative sites comprised of thought leaders and first-class treatment programs focused on blood cancer. Other goals of the consortium include:

  • Conducting clinical trials in blood cancer with efficiency and quality
  • Designing and implementing investigator-initiated and industry-sponsored clinical trials
  • Partnering with pharmaceutical and biotech companies to develop new compounds for the treatment of blood cancer

Phase I-III Research Program:

  • Leukemia, Myelodysplastic Syndrome and Myeloproliferative Disorders
  • Lymphoma and Chronic Lymphocytic Leukemia
  • Multiple Myeloma and Related Plasma Cell Malignancies
  • Autologous and Allogeneic Blood and Marrow Transplant

Advantages of Collaboration:

  • Infrastructure and further support in expertise in clinical research
  • Extensive clinical trial menu specializing in hematology trials
  • Increased accruals to provide innovative therapies to patients
  • Scientific collaboration with other investigators in the field
  • Rapid access to novel therapies Increased breadth of research disease program
  • Ability to expedite the process for drug approval from Phase I - III

Blood Cancer Research Consortium Sites

  • Sarah Cannon Center for Blood Cancer- Nashville, TN
  • Colorado Blood Cancer Institute- Denver, CO
  • Texas Transplant Institute- San Antonio and Austin, TX
  • Oncology Hematology Care- Cincinnati, OH